BGI, one of the world’s largest genome sequencing companies, is targeting an A-share Chinese listing to help raise capital for development and acquisitions, some of them overseas.
However, it is unclear when the eye-catching initial public offering will see light.
The company, which previously abandoned plans to list in Hong Kong, aims to launch the IPO by the end of the year, Mao Mao, BGI's newly appointed chief science officer, told Chinese media last week.
But one person with knowledge of the matter told FinanceAsia that BGI is “very unlikely” to go public within the year, given the current...
¬ Haymarket Media Limited. All rights reserved.
